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To the Editor:
Chromosomal abnormalities are an important
cause of epilepsy [Singh et al., 2002], which might
be the presenting symptom in the context of a
specific syndrome. A recent article by Langer et al.
[2006] reports on a translocation t(2;15) with deletion
at 2q24-q31 in a girl with epilepsy, dysmorphic
features, and severe developmental delay. As this
case adds to the growing list of severe epilepsy
associated with deletions at chromosome 2q, it
deserves complementary information and com-
ments.
We would like to point out that wedescribed a very
similar case in a previous report on a girl carrying a
deletion at chromosome 2q24 [Pereira et al., 2004]. In
our patient as well as in the patient described by
Langer et al. [2006], epileptic seizures first started
early in life, at 2 and 3 months 1/2, respectively.
Seizures were frequent in both cases and were
accompanied by severe apnea. Both children had
severe developmental delay and no speech devel-
opment. In the two patients, additional common
features were encountered, including microcephaly,
downslanting and small palpebral fissures, and
abnormal ears.
Despite the clear similarities existing between
those two cases, other clinical manifestations were
not shared in common by the two patients. Our
patient had single palmar creases bilaterally and
partial syndactyly between the 2nd and 3rd toes, and
cardiac examination showed a small interventricular
communication. In contrast, the patient in Langer
et al. [2006] had micrognathia, blepharophimosis,
hypertelorism, and coloboma of the iris and retina.
This is reminiscent of the clinical features described
in other cases of del(2)(q31q33) [Ramer et al., 1990]
and del(2)(q24–q31) [Nixon et al., 1997].
The size and the boundaries of the respective
deleted areas vary from one patient to another
(Fig. 1) and this might well explain the clinical
differences described above. In the case of the
patient described by Langer et al. [2006], the
translocation breakpoint at 15q14 might also partici-
pate in the phenotype. In this latter patient, the
deleted region on chromosome 2 spans about 13 Mb
between markers rs198688 and rs1399959 and
contains up to 76 genes including SCN1A and SCN2A,
the mutations of which have already been associated
with various epileptic syndromes [Meisler and
Kearney, 2005]. Our critical region was of smaller
size and spanned3–7Mb [Pereira et al., 2004] (Fig. 1).
It is fully included within the 13 Mb-deleted area
described by Langer et al. [2006] (Fig. 1) and ‘only’
contains 32 genes at most and 10 genes at least,
including SCN1A and SCN2A as well as three other
sodium channel genes (see the human genome
sequence at UCSC web site: http://genome.ucsc.
edu) [Pereira et al., 2004].
Epilepsy was not seen in the patient reported by
Nixon et al. [1997]. The data reported by Langer et al.
[2006] thus reinforce our previous hypothesis [Per-
eira et al., 2004], that the epileptic phenotype in these
patients is specifically associated with the deletion of
the genomic area comprised between marker
D2S354 (marker d in Fig. 1) and marker D2S2345
(h) at most. This genomic region actually comprises
the cluster of five sodium channel genes mentioned
above. As already discussed [Pereira et al., 2004;
Langer et al., 2006], the seizures in the affected
children might well be due to loss or haploinsuffi-
ciency of one or several of these genes. Such deletion
events might remain undetected and hence might be
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underestimated in other patients with severe epi-
lepsy and should thus probably be more system-
atically searched using the appropriate polymorphic
markers (Fig. 1).
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FIG. 1. Map of the deleted regions in the three patients with various del(2)(q24-q31) reported in (A) Nixon et al. [1997], (B) Pereira et al. [2004], and (C) Langer et al.
[2006]. Markers are shown from centromere to telomere. a: rs198688, (b) rs719931, (c) D2S156, (d) D2S354, (e) D2S2157, (f) D2S382, (g) D2S111, (h) D2S2345, (i)
D2S294, (j) D2S2284, (k) rs1362496, (l) D2S333, (m) rs1399959, (n) D2S2314, (o) D2S117. Squares represent the maximal size of the deleted regions. þ, undeleted
markers;, deleted marker;, deletion status could neither be determined nor deduced. Gray symbols represent those markers with data available. Non-gray symbols
represent the deletion status that was inferred assuming one single and contiguous deleted area in each patient. Physical distances between markers are based on the
human genome sequence at UCSC web site (http://genome.ucsc.edu). Mb: Megabases.
CORRESPONDENCE 1355
American Journal of Medical Genetics Part A: DOI 10.1002/ajmg.a
